Thompson Tamar 4

What Happened
Tamar Thompson, a director of Catalyst Pharmaceuticals (CPRX), reported dispositions related to the July 15, 2026 closing of Catalyst's acquisition by Angelini Pharma. Thompson sold 3,773 shares at $31.50 each, generating $118,850. In addition, several option and restricted-stock-unit (RSU) awards were cancelled and converted into cash payments under the merger agreement (these derivative disposals are reported at $0 on the Form 4).

Key Details

• Transaction date: 2026-07-15; Form 4 filed 2026-07-17.
• Open-market sale: 3,773 shares @ $31.50 = $118,850.
• Derivative disposals (reported as $0 on Form 4): 40,000; 29,524; 23,248; 18,115; 1,414; 1,894; and 5,468 shares (these represent options and RSUs cancelled in the Merger).
• Footnotes: the disposals occurred in connection with consummation of the merger with Angelini Pharma S.p.A. Options were cancelled and converted into cash equal to (31.50 less the option strike) × number of option shares; RSUs were cancelled and converted into cash equal to $31.50 × number of RSU shares. Payments were without interest and net of applicable tax withholdings.
• Vesting: each reported option was fully vested and all options/RSUs vested in full in connection with the Merger.
• Shares owned after transaction: not disclosed in the provided filing.

Context
This activity reflects merger-related cash-outs rather than routine open-market trading or a voluntary sale for portfolio repositioning. The Form 4 shows the cash-out structure (stock and derivatives converted into cash under the acquisition terms); it does not provide the specific cash amounts for the derivative conversions on the face of the filing. Such merger-driven dispositions are common when an acquirer pays cash for outstanding equity awards.